New Blood Test Detects Hidden Cancer

A groundbreaking blood test called HaystackMRD is revolutionizing cancer patient care by detecting microscopic amounts of cancer that traditional methods often overlook. Developed by Haystack Oncology and made clinically available in late 2024, this test analyzes circulating tumor DNA (ctDNA) in a patient's blood, offering a highly sensitive indicator of residual disease.

This innovative approach addresses a critical need for clearer information after treatments like surgery. Imaging techniques like MRIs and CT scans are standard, but HaystackMRD provides a more precise assessment of whether cancer has been completely eradicated or if it has returned. This data empowers physicians and patients, moving decision-making towards a more data-driven process.

The HaystackMRD test is customized for each patient using their tumor tissue, with results typically available in 30 days for initial tests and seven to ten days for follow-ups. Johns Hopkins researchers initiated the decades-long development, and the test recently received FDA Breakthrough Device Designation in August. Thousands of tests have been administered globally, primarily in the U.S., offering hope for earlier detection and better treatment strategies for solid tumor cancers.